Shang Lin to Protein Kinase Inhibitors
This is a "connection" page, showing publications Shang Lin has written about Protein Kinase Inhibitors.
Connection Strength
0.058
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.058
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.